M Sattler Selected Research

Multiple Myeloma

1/2017	The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment.
7/2001	Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

M Sattler Research Topics

Disease

5	Neoplasms (Cancer) 04/2012 - 07/2000
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2012 - 09/2010
2	Multiple Myeloma 01/2017 - 07/2001
2	Carcinogenesis 01/2017 - 01/2000
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 02/2011 - 04/2001
1	Trypanosomiasis 01/2017
1	Plasma Cell Leukemia 07/2001
1	Type 2 Diabetes Mellitus (MODY) 09/2000
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 07/2000

Drug/Important Bio-Agent (IBA)

3	Phosphotransferases (Kinase)IBA 04/2012 - 07/2000
2	Tyrosine (L-Tyrosine)FDA Link 10/2012 - 09/2010
1	Transcription Factors (Transcription Factor)IBA 01/2017
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 01/2017
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2012
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 02/2011
1	Protein Kinases (Protein Kinase)IBA 07/2001
1	Protein Kinase CIBA 07/2001
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2001
1	Biological ProductsIBA 04/2001
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 04/2001
1	Endothelin-1 (Endothelin 1)IBA 09/2000
1	Stem Cell FactorIBA 07/2000
1	Imatinib Mesylate (Gleevec)FDA Link 07/2000
1	Tyrosine Kinase InhibitorsIBA 07/2000
1	PaxillinIBA 01/2000
1	Proteins (Proteins, Gene)FDA Link 01/2000

Therapy/Procedure

3	Therapeutics 01/2017 - 09/2010